Brentuximab vedotin

维布妥昔单抗

Report date: 2026/05/26 20:00:28
First In Class

Base Information

Drug NameBrentuximab vedotin
Drug Alias Name布妥昔单抗brentuximab vedotinabrentuximabum vedotinum本妥昔单抗泊仁妥西布凡多汀 +[14] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-Tumor necrosis factor receptor superfamily member 8
TargetsTumor necrosis factor receptor superfamily member 8Tubulin
Therapy Area/IndicationsSolid tumoursGraft vs Host DiseaseScleroderma, Diffuse +[34] 
Global Approved IndicationsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticHodgkin Disease
Approved Indications in ChinaLymphoma, Large-Cell, AnaplasticHodgkin Disease
Original Approved Country/TerritoryUnited States
Original Approved Date2011/08/19
Country/TerritoryCzechiaBelgiumBulgaria +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSeagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdUniversity Medical Center GroningenSeagen Inc +[13] 
Inactive CompaniesWashington University School Of MedicineUniversity Of BirminghamBsp Pharmaceuticals Srl +[11] 
Active IndicationsScleroderma, DiffuseScleroderma, SystemicHematologic Diseases +[16] 
Inactive IndicationsSolid tumoursGraft vs Host DiseaseLupus Erythematosus, Systemic +[18] 

Other Information

ATC CodeL01XC12
Related LinksWikipediaDrugBankKEGG